Virbagen L
Revised: May 2012
AN: 01382/2011
SUMMARY OF PRODUCT CHARACTERISTICS |
|||
1. |
NAME OF THE IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCT |
||
|
VIRBAGEN L |
||
2. |
QUALITATIVE AND QUANTITATIVE COMPOSITION |
||
|
Active ingredients: formula and titre per dose Leptospira canicola • titre before inactivation ………………………………… Leptospira icterohaemorrhagiae • titre before inactivation ………………………………… |
833.106 bacteria/ml 833.106 bacteria/ml |
|
|
0.038 ml of each, in buffered isotonic solution with residual culture medium. |
||
|
|
||
|
For a full list of excipients, see section 6.1 |
||
3. |
PHARMACEUTICAL FORM |
||
|
Suspension for injection |
||
4. |
CLINICAL PARTICULARS |
||
4.1 |
Target species |
||
|
Dogs |
||
4.2 |
Indications for use, specifying the target species |
||
|
For the active immunisation of dogs from 8 weeks of age to reduce clinical signs of disease. A serological response occurs by 3 weeks after the second dose. The duration of protection lasts 12 months after immunisation. |
||
4.3 |
Contraindications |
||
|
Do not vaccinate females during pregnancy. |
||
4.4 |
Special warnings |
||
|
None |
||
4.5 |
Special precautions for use |
||
i. |
Special precautions for use in animals |
||
|
The vaccine should be administered in accordance with the usual aseptic conditions for vaccination. It is recommended that animals be treated for intestinal parasites at least 10 days prior to vaccination. Vaccinate only healthy dogs. Avoid exposure of the animal to infection for 21 days following vaccination |
||
ii. |
Special precautions for the person administering the veterinary medicinal product to animals |
||
|
The active ingredients of the vaccine are inactivated but normal precautions should be taken to avoid contact with the skin and self-injection. In the event of accidental self-injection, seek medical advice immediately. |
||
4.6 |
Adverse reactions (frequency and seriousness) |
||
|
Transient itching, pain and/or swelling may occur at the injection site. Occasional hypersensitivity reactions may occur but the incidence of these is rare. If anaphylactic reactions should occur, immediately administer corticotherapy (if possible, high doses by I.V. route) or antihistamines associated with usual treatment against anaphylactic shock. |
||
4.7 |
Use during pregnancy, lactation or lay |
||
|
Do not use in pregnant animals. |
||
4.8 |
Interaction with other medicinal products and other forms of interaction |
||
|
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with live canine distemper, canine adenovirus, canine parovirus and canine parainfluenza-virus vaccines. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be decided on a case by case basis. |
||
4.9 |
Amounts to be administered and administration route |
||
|
Shake well before use. Primary vaccination - Puppies of 8-9 weeks of age can be subcutaneously administered one dose of 1 ml of VIRBAGEN L followed by another one 3-4 weeks later but never before the age of 12 weeks. - Puppies older than 9 weeks can be subcutaneously administered one dose of 1 ml of VIRBAGEN L followed by another one 3-4 weeks later. Booster vaccination Annual revaccination with a single subcutaneous 1 ml dose of VIRBAGEN® L. |
||
4.10 |
Overdose (symptoms, emergency procedures, antidotes), if necessary |
||
|
TTransient itching, pain and/or swelling similar to that described in section 4.6. may occur at the site of injection. |
||
4.11 |
Withdrawal period |
||
|
Not applicable |
||
5. |
IMMUNOLOGICAL PROPERTIES |
||
|
ATC Vet Code: QI07AB01 To stimulate active immunity against Leptospira canicola and Leptospira ictero-haemorrhagiae. |
||
6. |
PHARMACEUTICAL PARTICULARS |
||
6.1 |
List of excipients |
||
|
Sucrose Potassium hydrogen phosphate Potassium dihydrogen phosphate Tryptone Water for injection |
||
6.2 |
Incompatibilities |
||
|
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with live canine distemper, canine adenovirus, canine parovirus and canine parainfluenza-virus vaccines. Do not mix with any other veterinary medicinal product. |
||
6.3 |
Shelf life |
||
|
Shelf-life of the veterinary medicinal product as packaged for sale: 24 months Shelf-life after first opening the immediate packaging: use immediately |
||
6.4 |
Special precautions for storage |
||
|
Store and transport in the original package at a temperature of 4°C + 2°C. Protect from light. Do not freeze. |
6.5 |
Nature and composition of immediate packaging |
|
Containers Insulin-type vial - 3 ml - Diameter 16, 25/38.5. Neutral borosilicate type I glass complying with the European Pharmacopoeia, current edition. Closures Elastomer stoppers - Internal diameter 7 mm. External diameter 13 mm, complying with the European Pharmacopoeia, current edition. Sealing Perforated aluminium capsule. Size 10 x 1 and 50 x 1 doses Not all pack sizes may be marketed |
6.6 |
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate |
|
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements. |
7. |
MARKETING AUTHORISATION HOLDER |
|
Virbac S.A. 1ère avenue - 2065 m – L.I.D. 06516 Carros Cedex France |
8. |
MARKETING AUTHORISATION NUMBER |
|
Vm 05653/4047 |
9. |
DATE OF FIRST AUTHORISATION |
|
Date : 17 October 2005 |
10. |
DATE OF REVISION OF THE TEXT |
|
Date : May 2012 |
Page 4 of 4